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INTRODUCTION
Lysophosphatidic acid (LPA) is a pleiotropic bioactive lipid produced from extracellular lysophospholipids by autotaxin (ATX), as well as derived from membrane glycerophospholipids by phospholipases (Aoki, 2004; Hishikawa et al., 2014; Perrakis and Moolenaar, 2014) , to produce a range of chemical species with varied fatty acid chain length and saturation. LPA is present in nearly all cells, tissues, and fluids of the body (Mirendil et al., 2013) and its effects are mediated by cognate cell-surface G protein-coupled receptors (GPCRs) consisting of six family members designated LPA 1 -LPA 6 (Kihara et al., 2014 ) that couple to heterotrimeric G protein complexes to activate downstream signaling pathways. Targeted deletion of the LPA receptors has revealed physiological effects on every organ system examined thus far, with receptor dysregulation linked to a range of disease indications including hydrocephalus (Yung et al., 2011) , infertility (Ye et al., 2005) , fibrosis (Tager et al., 2008) , pain (Inoue et al., 2004) , and cancer (Mills and Moolenaar, 2003) . Three of the six LPA receptors, including LPA 1 (Kihara et al., 2014) , are part of a larger lysophospholipid receptor family (the EDG family) that includes the sphingosine 1-phosphate (S1P) receptors, of which the structure of one member (S1P 1 ) has been reported . The closely related cannabinoid receptor CB 1 (Hecht et al., 1996; Matsuda et al., 1990) interacts with endogenous ligands structurally related to LPA raising the question of potential polypharmacology between the two receptors, effectively connecting these signaling systems. Additional structural details for this family will improve our understanding of their associated function and physiology.
RESULTS

Design of LPA 1 Ligands for Structural Studies
A key for success in GPCR structure determination is the identification of a ligand that stabilizes the receptor into a single and stable conformation. To facilitate finding such a ligand, a stability assay based on analytical size exclusion chromatography (aSEC) was developed and used to screen a library of compounds ( Figure S1 ). The compound used for initial studies of LPA 1 , ONO-9780307 (Table S1 , Figure S5A and Supplemental Experimental Procedures), was selected from this library based on the initial SEC stability assay data ( Figure S1 ) (Tanaka et al., 2011) . This assay was used in place of the more traditional CPM assay (Alexandrov et al., 2008) to allow early access to stability data without the need for pure receptor protein. Using insights gained from the initial structure, several analogs of ONO-9780307 were designed by considering lipophilicity, structural diversity, and potential metabolic stability. These analogs were synthesized (Supplemental Experimental Procedures), tested for stability induction, and used to generate additional co-crystal structures (Table S1 ). The design feature of ONO-9910539 ( Figure S5B ) is an acetyl group for enhanced polar interactions and reduced lipophilicity. The design of ONO-3080573 ( Figure S3B ) replaced a methylene and the pyrrole ring with an ether and phenyl ring, respectively, to both reduce torsional strain and increase structural diversity and potential metabolic stability.
Structure Determination of LPA 1 -ONO-9780307, LPA 1 -ONO-9910539, and LPA1- To facilitate crystallization, a thermostabilized b 562 RIL (bRIL) (Chun et al., 2012) , was inserted into the third intracellular loop (3IL) at Ballesteros index positions 5.66 (R233) and 6.24 (R247) (Ballesteros and Weinstein, 1995) , and thirty-eight residues were truncated from the carboxyl terminus (C terminus). With this engineered construct (LPA 1 -bRIL) in complex with compounds ONO-9780307 and ONO-9910539, crystals were produced in LCP supplemented with cholesterol that diffracted to a final resolution of 3.0 Å and 2.9 Å , respectively, and supported structure solution ( Figure 1A ). Despite similar stability induction for ONO-3080573 ( Figure S1 ), we were unable to crystallize this compound with the original LPA 1 -bRIL construct. In order to further improve stability and reduce conformational heterogeneity for crystallization in the presence of ONO-3080573, a series of disulfide bonds were engineered into various sites within the extracellular half of the transmembrane region of LPA 1 -bRIL, and one was selected based on superior expression and stability analysis (dsLPA 1 -bRIL) (Figures 2A and C) . The effect of disulfide bond engineering at this site was evaluated using signaling in response to LPA concentration in a calcium mobilization assay ( Figure 2B ). To reduce conformational heterogeneity, bRIL was modified by replacing a disordered loop with a short linker (mbRIL). Crystals of dsLPA 1 -mbRIL in complex with ONO-3080573 were grown in a LCP cholesterol mixture and diffracted to 2.9Å ( Figure 2D ). While there are clear differences in experimental electron density for the ligands ( Figure S2 ), aside from small conformational changes in and around the binding pocket, the receptor structures are highly analogous.
Overall Structural Features of LPA 1 in Complex with ONO-9780307
The initial co-crystal structure of LPA 1 -bRIL in the antagonist state with the compound ONO-9780307 is used for a general description of the receptor. The main fold of the antagonist bound LPA 1 receptor is similar to other inactive class A GPCRs, with a canonical seven-transmembrane a-helical bundle (Figure 1A) . The N terminus of LPA 1 forms a six-turn alpha helix similar in length and orientation to the equivalent residues in S1P 1 , but with an additional disulfide bond linking the N-terminal capping helix to extracellular loop 2 (ECL2), resulting in additional fold stability. The N terminus packs tightly against ECL1 and ECL2 and provides charged and polar amino acid side chains for interactions within the ligand-binding pocket. The ligand, ONO-9780307, positions its branching aromatic indane and dimethoxy phenyl rings adjacent to each other in the spherical binding pocket. This positioning requires a strained eclipsed conformation of the torsion angle on the bond adjacent to the indane ring, with a difference of 9.6 kcal/mol between the observed conformation and the local energy minimum estimated by gas-phase quantum mechanics calculations. The ligand conformation associated with the local energy minimum is not able to bind in the pocket due to projected clashes with TMVI ( Figure 1B ).
Structural Comparison of the LPA 1 and S1P 1 Receptors The relative orientation of LPA 1 helices is similar to the S1P 1 receptor, which was expected given the similarity in both primary sequence (41% identical in the transmembrane region) and recognition of lysophospholipid endogenous ligands . The primary point of divergence occurs at the tip of TMI, which is positioned 3 Å closer to TMVII compared to S1P 1 ( Figure 3A ). This helical repositioning closes a gap between TMI and TMVII, which was postulated to enable access of hydrophobic ligands to the occluded extracellular binding pocket via the membrane for S1P 1 . The short segment between TMI and the N-terminal capping helix (ECL0) is helical in S1P 1 but lacks secondary structure in LPA 1 . This change may open access to the ligand binding pocket from the extracellular space through increased flexibility and may also contribute to the inward shift of TMI through a release of secondary structure steric constraints. Interestingly, ECL1 and ECL2 are comparable between the two receptors, whereas the position of the third extracellular loop (ECL3) diverges from the S1P 1 receptor by up to 8 Å at the furthest point, resulting in a loss of interactions between this loop and the rest of the extracellular region ( Figure 3A ). The overall result is the opening of a ligand access port into the extracellular milieu for LPA 1 , while access from the plasma membrane is closed ( Figure 3A ). These global changes combined with residue substitutions generate a binding pocket for LPA 1 that is more spherical compared to S1P 1 ( Figure 3B ). This characteristic supports the finding that LPA 1 has the ability to recognize a more diverse repertoire of chemical species of endogenous ligands with acyl chains of different lengths and globular conformations beyond the commonly used LPA 18:1 sn1. Three sequence substitutions can be identified that alter both the shape and polarity of the LPA receptor binding pocket compared to S1P receptors. In LPA receptors, position 3.33 is occupied by an aspartate residue (Asp129 3.33 in LPA 1 ), whereas S1P receptors have a conserved phenylalanine that serves an important role in ligand recognition (van Loenen et al., 2011) . At position 5.43, LPA receptors possess a tryptophan residue (Trp210 5.43 in LPA 1 ), contrasting with a cysteine residue at this position in most S1P receptors. Finally, LPA receptors have a glycine (Gly274 6.51 in LPA 1 ) at position 6.51, contrasting with a leucine or alanine that forms important van der Waals interactions with the S1P ligands ( Figure 3B ). The configuration of the extracellular region is constrained by two intraloop disulfide bonds in ECL2 and ECL3 and a disulfide bond connecting ECL2 with the N terminus. Although the electron density for the ECL3 loop is poor compared to the rest of the structure, the approximate position could be properly determined and is further from the N-terminal helix compared to S1P 1 . In S1P 1 Lys285 in this region forms a cation dipole interaction with the C-terminal end of the capping helix, an interaction that is missing in LPA 1 . TMI is shifted 3 Å closer to TMVII at the tip compared to S1P 1 and ECL0 is a loop in LPA 1 . Neither ECL0 nor ECL3 are involved in crystal contacts. (B). The shape of the LPA 1 binding pocket is spherical in nature (solid surface) compared to the more linear binding pocket of S1P 1 (blue mesh surface). This difference is caused by three changes in the amino acid composition between the two receptors. The first at position 3.33 is an aspartate in LPA 1 and a phenylalanine in S1P 1 . The second at position 5.43 is a tryptophan in LPA 1 and a cysteine in S1P 1 . Finally at position 6.51 LPA 1 has a glycine, whereas S1P 1 has a leucine. The reduction in side chain bulk at this position opens a sub-pocket occupied by the indane ring of the antagonist series.
Molecular Dynamics Analysis Supports Ligand Access from Extracellular Space
The divergent position of TMI in LPA 1 compared to S1P 1 is attributable to both enhanced polar interactions and a substantial reduction in volume at the interface of TMI and TMVII (Figures 4A and 4B) . In order to further understand the mode of ligand access for both LPA 1 and S1P 1 , comparative molecular dynamics simulations of both receptors were completed, with and without their respective ligands, and the distance between the TMI and TMVII helices was analyzed over the course of three independent 100 ns simulations for each receptor system. Based on this analysis, it is clear that the distance between TMI and TMVII in LPA 1 is indeed smaller and less variable compared to that observed for S1P 1 . The distances diverge most noticeably at the extracellular tip of the helices, with a difference of approximately 7 Å between LPA 1 and S1P 1 in the absence of ligand ( Figure 4C ). Overall, these results strengthen the conclusion that sequence differences between TMI and TMVII on LPA 1 and S1P 1 result in an altered ligand access path, whereby LPA 1 preferentially receives ligands from the extracellular milieu compared to membrane access for S1P 1 ligands.
LPA 1 Ligand Binding Interactions with ONO-9780307, ONO-9910539, and ONO-3080573
Despite similar endogenous ligands, similar overall structural characteristics, and mutagenesis studies suggesting simple interchangeability between LPA 1 and S1P 1 (Wang et al., 2001) , structural comparisons of the pocket shape and polarity revealed substantial divergence between the two receptors. At the top of polar region of the binding pocket, the carboxylic acid of ONO-9780307 interacts through polar and ionic bonds with residues His40, Lys39, and Tyr34, all of which are located on the N-terminal capping helix and ECL0 loop. Across the LPA family, both Lys39 and Tyr34 are highly conserved, however, His40 is unique to LPA 1 and its protonation may be important for high-affinity interactions with the carboxylic acid of ONO-9780307. Although direct experimental support is needed to draw definitive conclusions, calculations of binding energy between wild-type LPA 1 with a protonated His40 and ONO-9780307 compared to a His40Ala in silico mutation showed a greater than 1 kcal/mol difference in binding affinity supporting the hypothesis that this position could be partially responsible , this helical position allows access of ligand (ML056 shown in green carbon sticks) in the plasma membrane to the binding pocket of S1P 1 . (B) The position of TMI in LPA 1 is closer to TMVII closing access of ligand (ONO-9780307 shown in green carbon sticks) in the plasma membrane to the binding pocket. The closer packing of TMI relative to S1P 1 may be driven by the presence of Glu301 7.43 , which forms a hydrogen bond interaction with the backbone of Gly56
1.39 and Val59 1.42 .
(C) Molecular dynamics analysis of the distance between TMI and TMVII measured at four locations represented by a box plot for each measurement with the minimum and maximum indicated by vertical lines. The measurements correspond to the distances shown in Å monitored over the course of the simulation. The distance between the two helices is consistently larger and more variable for S1P 1 than LPA 1 both with and without ML056 and ONO-9780307 ligands, respectively.
for the observed selectivity of this class of antagonists for LPA 1 over LPA 2 and LPA 3 (Table S2 , Figure S3 , Figure S4 and Supplemental Experimental Procedures) (Beard et al., 2013 Figure 5A ). Ligand design strategies for engaging this polarity while reducing lipophilicity were implemented with ONO-9910539, which features an acetyl group in the para position of the phenyl ring, placing a hydrogen bond acceptor for interaction with the indole nitrogen of Trp210 5.43 ( Figure 5B ). The torsionally strained bioactive conformation of ONO-9780307 helps to fill the large spherical binding pocket, placing the indane ring adjacent to Gly274 6.51 on TMVI ( Figure 1B and 5A). Ligand design strategies were implemented for ONO-3080573, which alleviates this torsional strain by replacing the methylene linker with an ether moiety ( Figure 5B ). This replacement was coupled with replacement of the metabolically labile pyrrole ring found in ONO-9780307 and ONO-9910439 with a phenyl ring, which differentially positions the carboxylic acid, breaking interactions with Arg124 3.28 , His40, and Tyr34 but gaining an interaction with Lys294 7.36 .
Intersecting Endocannabinoid Pharmacology
The additional polarity provided by Asp129 3.33 and Trp210 5.43 in the hydrophobic binding pocket may have implications for specifying the preference of LPA receptors for long unsaturated acyl chains, serve as a trigger for agonist induced conformational changes, and is interesting in the context of GPCR phylogenetic evolution. The presence of a tryptophan in this position only occurs in 1% of all class A receptors and is unique to the lysophospholipid and cannabinoid receptors (Van Durme et al., 2006) . The most abundant endogenous agonist for the cannabinoid receptor CB 1 is 2-arachidonyl glycerol (2-AG; 1,3-dihydroxy-2-propanyl (5Z,8Z,11Z,14Z)-5,8,11,14-eicosatetraenoate) (Stella et al., 1997; Sugiura et al., 1997) . Despite binding at a much lower affinity than the other identified endocannabinoid, anandamide, its higher relative abundance makes 2-AG a major signaling molecule for cannabinoid receptors (Stella et al., 1997) . Interestingly, 2-AG is phosphorylated and converted to 2-arachidonyl phosphatidic acid (2-ALPA) through the action of monoacylglycerol (MAG) kinase/acyl glycerol kinase (AGK) (Kanoh et al., 1986) , producing a potential signaling molecule accommodated by the spherical LPA 1 binding pocket, although the relative abundance of 2-ALPA has not been investigated. Furthermore, an alternative biosynthetic pathway has been reported for the production of anandamide that progresses through a lysophospholipid analog (pAEA), adding support for the idea of metabolic cross-talk between LPA and cannabinoid receptor systems ( Figure 6A ) (Liu et al., 2006) .
The ability of lysophosphatidic acid derivatives of cannabinoid ligands to bind and activate LPA 1 was tested both with 2-ALPA and pAEA using molecular modeling ( Figures 6B and C) and in receptor signaling assays previously used to define LPA 1 as an LPA receptor ( Figure 6D) . A model for lipid agonist binding generated through molecular modeling was used to dock the endogenous ligands into the LPA 1 binding pocket. The slight expansion of the binding pocket through rotameric shifts of A) The LPA, S1P, and cannabinoid receptors are grouped in the same clade based on a sequence alignment of the transmembrane region. LPA and cannabinoid receptors are proposed to overlap in ligand specificity when binding polyunsaturated acyl chains delimited by different head group requirements. The biosynthetic map details the conversion of standard phospholipids to both LPA and CB receptor agonists through common pathways. Both known agonists for the cannabinoid system (2-AG and AEA) are one enzymatic step away from LPA ligands via phosphorylation of the head group (2-ALPA and pAEA). (B) Molecular modeling of the endogenous agonist lysophosphatidic acid with an 18 carbon acyl chain (LPA). In the presence of agonist, both Trp271 6.48 and Trp210 5.43 are predicted to change rotameric states to increase the volume of the binding pocket and direct the respective aromatic p clouds toward the bound ligand. The predicted agonist binding pocket is capable of docking 2-ALPA and pAEA, which are generated through enzymatic action from endogenous cannabinoids.
(legend continued on next page) the double bonds of the phosphorylated cannabinoid ligands ( Figure 6B ). The ability of both 2-ALPA and pAEA to bind in the modeled agonist pocket without significant ligand strain, supports the notion that the hydrophobic binding pockets of LPA 1 and CB 1 can indeed bind the same, poly-unsaturated acyl chains with metabolically interconvertible head groups. The molecular modeling provided sufficient rationale for testing both 2-ALPA and pAEA in LPA 1 signaling assays. Remarkably, all phosphorylated ligands produced robust signaling as judged by calcium response and cAMP inhibition in stable cell lines heterologously expressing LPA 1 (Fukushima et al., 1998) . Further, a neurite retraction assay, which measures cell morphology changes mediated by LPA 1 , showed robust activation by pAEA ( Figure 6D ). Neurite retraction involves activation of the small GTPase Rho that can also activate F-actin stress fibers in adherent cells, and this classic response was also activated by pAEA. Together these results highlight the selectivity of the phosphate headgroup on LPA 1 in addition to the promiscuity of the binding site for acyl chain geometry and degree of saturation, wherein chemically distinct ligands that are capable of accessing this space can produce common responses of receptor activation and down-stream signaling.
DISCUSSION
The growing family of GPCRs mediating membrane-derived lysophospholipid signals (Kihara et al., 2014 ) is remarkable for its ability to respond to diverse changes in the cellular milieu through multiple signaling mechanisms, and to discriminate structurally similar molecules. The ability of antagonist structures to inform receptor agonist binding is atypical, yet may reflect the evolutionary selection of binding pockets for lipid ligands that are produced from precursor reservoirs within which the receptors are embedded, which may further contribute to constitutive or inverse agonist activities (Bond and Ijzerman, 2006) . A somewhat surprising result was the structural preference of LPA 1 for ligand access from the extracellular milieu, rather than via the membrane as was reported for S1P 1 . Nevertheless, this structural prediction is supported by the biological existence and routine experimental use of albumin bound LPA (Postma et al., 1996) to activate LPA 1 (Fukushima et al., 1998) , and is further consistent with the proposed delivery of LPA by its major extracellular biosynthetic enzyme, autotaxin, via a hydrophobic channel identified in its crystal structure (Nishimasu et al., 2011) . The structure of LPA 1 identified binding interactions between antagonist and His40, having a calculated pKa of 6.8 and 4.5 in the presence and absence of ligand, respectively. Although speculative, computational analysis indicates that full protonation of His40 increases ligand binding affinity by more than 1 kcal/mol (Beard et al., 2013) . If substantiated through direct experimental observation, this could further support the hypothesis that the neoplastic activity of LPA 1 is enhanced (Hama et al., 2004; Hausmann et al., 2011; Mills and Moolenaar, 2003; Perrakis and Moolenaar, 2014) in the acidic environment associated with hypoxic tumors (Herr et al., 2011; Justus et al., 2013; Kim et al., 2006; Tannock and Rotin, 1989; Wojtkowiak et al., 2011) . Structural analyses predicts a functional complementarity and/or redundancy between CB 1 and LPA 1 depending on the balance of phosphorylation states for AEA and 2-AG in particular, since it is a favored substrate of MAG kinase, at least in the brain (Kanoh et al., 1986) . The interplay of these receptor-ligand systems may contribute to phenotypic variability seen among LPA 1 knockout strains and variable null mutant survival within susceptible strains that are attributable to brain phenotypes (Contos et al., 2000; MatasRico et al., 2008) , since brain expression of both receptors, along with ligand metabolism, is widespread and can overlap as occurs in oligodendrocytes (Benito et al., 2007; Weiner et al., 1998) . Complementary access to LPA 1 through phosphorylated CB1 ligands-and vice versa-represent examples of a single molecular species that could serve as both a primary receptor modulator and simultaneous prodrug for a different receptor, as represented by the endocannabinoids acting at their receptors, with phosphorylation producing selective LPA receptor ligands. Currently, compounds developed to target LPA receptors have entered Phase II clinical trials for pulmonary fibrosis and systemic sclerosis. Compounds exhibiting antagonist and/or agonist activity for both the CB 1 and LPA 1 receptors have yet to be tested but may be superior for certain indications.
EXPERIMENTAL PROCEDURES Ligand Selection Optimization and Stability Analysis
Compounds based on a 3-pyrrolylpropionic acid core were selected from a library of previously developed LPA 1 antagonists based on superior receptor stability induction properties (Tanaka et al., 2011) . From this initial screen, ONO-9780307 was selected for structural determination. Analysis of the binding pocket revealed three regions for improved interactions. ONO-9910539 was designed to improve polar interactions with Trp210 5.43 through the introduction of an acetyl moiety on the phenyl ring, and ONO-3080573 was designed to reduce torsional strain associated with the bioactive conformation of the scaffold through the introduction of an ether linkage to the indane ring system ( Figure 5B , see also Supplemental Experimental Procedures, Figures  S3B and S5 and Table S1 ).
To measure the effect of compounds on the stability of the receptor, each compound was tested using a fluorescence based SEC stability assay. Briefly, after heating the GFP-tagged protein in the presence of ligand, an SEC profile of each data point was analyzed for fraction of folded protein, which was plotted as a function of temperature or time to determine approximate melting (C) Conformational root mean square fluctuation of LPA over the course of a 100 ns molecular dynamics simulation. The orientation of the ligand is consistent throughout the calculation indicating a reasonable starting point for modeling agonist interactions. (D) Analysis of intracellular signaling and cellular functions in B103 cells heterologously expressing full-length wild-type LPA 1 . The data are presented as mean normalized values (±SEM) to maximum responses induced by 3 mM 1-oleoyl-LPA (n = 3) for Ca 2+ mobilization assay, and by 10 mM forskolin (n = 3) for cAMP assay. For the Ca 2+ mobilization assay EC 50 values for LPA 18:1 sn1 (n = 3), 1-ALPA (n = 3), 2-ALPA (n = 2), and pAEA (n = 2) are 146 ± 74 nM, 1,125 ± 1,484 nM, 98 ± 143 nM, and 2,120 ± 3,885 nM, respectively. For the cAMP assay EC 50 values for LPA 18:1 sn1 (n = 2), 2-ALPA (n = 2), and pAEA (n = 2) are 0.345 ± 0.202 nM, 0.302 ± 0.54 nM, and 1.50 ± 2.04 nM, respectively. Neurite retraction was quantified under microscopic observation. Filamentous (F)-actin stress fibers, produced by Rho GTPase activation like neurite retraction, were also produced by pAEA stimulation. The representative cell morphologies were shown (scale bars, 50 mm). The F-actin stress fiber formation was observed after 15 min treatment with LPA and pAEA (scale bars, 10 mm).
temperature or half-life, respectively (see also Supplemental Experimental Procedures and Figure S1 ).
Crystallization and Diffraction Analysis of LPA 1 -bRIL and dsLPA 1 -mbRIL Synthetic cDNA encoding the full-length LPA 1 receptor was generated with a stabilized apocytochrome c (bRIL) protein inserted within the third intracellular loop at positions V232 and R248. Baculovirus directed expression in Spodoptera frugiperda (Sf9) insect cells was driven by the ie1 GP64 promoter with a cleavable HA signal sequence on the N terminus of the receptor and a cleavable purification tag consisting of a 103 poly histidine tag upstream of a FLAG epitope tag. The resulting construct (LPA 1 -bRIL) was expressed in Spodoptera frugiperda (Sf9) insect cells using the Bac-to-Bac baculovirus expression system (Invitrogen) at a yield of $1 mg/l and purified using IMAC chromatography (see also Supplemental Experimental Procedures). Protein samples of LPA 1 -bRIL and dsLPA 1 -mbRIL were reconstituted into lipidic cubic phase (LCP) and crystallization set-ups were performed at room temperature ($20 C). Data-collection quality crystals were obtained over a period of 30 days from precipitant condition containing 0.1 M sodium citrate (pH 5.5), 34% (À38% [v/v] PEG400 and 200 mM ammonium acetate; Figure 2D ). Crystals were harvested directly from LCP matrix and flash frozen in liquid nitrogen for diffraction analysis. X-ray diffraction data were collected on the 23ID-D/B beamline (GM/CA-CAT) at the Advanced Photon Source (Argonne, IL) using a 10 mm diameter minibeam with a MarMosaic 300 CCD detector. A rastering and data-collection strategy was followed as previously described (Cherezov et al., 2009; Hanson et al., 2012) . Unattenuated exposures of 5-10 s per degree were required to observe diffraction to $3 Å resolution. Due to the limited amount of data collected per crystal, a protocol similar to that developed for S1P 1 diffraction analysis was utilized to assemble the data. After data integration and scaling the structures were solved using molecular replacement followed by multiple cycles of refinement and rebuilding in order to generate the final model (see Supplemental Experimental Procedures). Statistics are presented in the crystallographic summary table (Table 1) .
Stability Engineering Using Disulfide Bond Addition
Candidates for disulfide bond engineering were generated computationally using algorithms implemented in BioLuminate (Schrö dinger, 2012) and similar to previously described procedures (see also Supplemental Experimental Procedures) (Salam et al., 2014) . Five potential candidates were identified on the extracellular half of the receptor consisting of two cysteine mutations per site to facilitate the formation of an additional disulfide bond. After generation of the mutant constructs and testing for expression, the double mutant D204C and V282C was selected for crystallization studies. This candidate was selected due to the enhanced expression profile as compared to the other four constructs, which showed little to no expression, as well as an enhanced thermal stability profile as characterized by the SEC thermal stability assay using highly purified receptor without a GFP tag (see also Supplemental Experimental Procedures).
Molecular Modeling and Dynamics Studies
Crystal structures of the S1P 1 (PDB ID: 3V2Y) and LPA 1 were prepared using the Schrö dinger Protein Preparation Wizard (Sastry et al., 2013) and embedded into a pre-equilibrated POPC (1-palmytoil-2-oleoyl-sn-glycero-3-phosphatidylcholine) lipid bilayer and solvated with water using the Desmond System Builder. Chloride ions were added to neutralize the system and the ionic strength was set to 0.15 M. The OPLS 2.1 force field (Schrö -dinger, 2014d) (Shivakumar et al., 2012) was utilized for all calculations and systems were relaxed using the default membrane relaxation protocol as implemented within the Schrö dinger package. Molecular Dynamics simulations were performed in the NPT ensemble at 300K and 1 atm pressure using Desmond (D.E. Shaw Research, 2014; Schrö dinger, 2014c) . The two receptors were analyzed both with and without ligands. Van der Waals and short range electrostatic interactions were cut off at 9 Å and smooth particle mesh Ewald (PME) (Essmann et al., 1995) method was employed for calculation of long range electrostatic interactions. The reversible reference system propagation algorithm (RESPA) multiple time step approach was used with a time step of 2 ps and long-ranged electrostatic interactions were computed every 6 ps . The temperature and pressure were controlled using a Nose-Hoover chain thermostat and Martyna-Tobias-Klein (Martyna et al., 1994) barostat, respectively. Three independent simulations of 100 ns each were performed for each system on a Nvidia GTX GPU card with coordinates saved every 1.2 ps for subsequent analysis. Molecular dynamics used for docking and modeling studies utilized similar system parameters but with a 1.2 ns simulation. Coordinates were saved every 1.2 ps and clustered by root mean square deviation of the residues within a 4 Å radius of the ligand. Representative structures of each cluster were tested for ability to dock endogenous ligands with minimal torsional strain. Change in binding affinity toward the ligand ONO-9780307 caused by either deprotonation of the residue His40 or its mutation to alanine was calculated using the Residue Scanning functionality in BioLuminate (Schrö dinger, 2014a) which incorporates the Prime MM-GBSA approach (Beard et al., 2013) . A cutoff of 1 kcal/mol was used as a threshold for defining potential effect from perturbation.
Quantum mechanical calculations for determining the energy penalty associated with the indane position observed in the crystal structures were carried out after geometry optimizations using Jaguar 8.6 (Schrö dinger, 2014b) at the B3LYP/6-31G** level of theory with and without torsional constraints on the indane ring region of the compound.
Functional Analysis Studies
HA-tagged full-length human receptor (LPA 1 ) and disulfide stabilized fulllength human receptor (dsLPA 1 ), DNAs were constructed and cloned into pCXN2.1 (Niwa et al., 1991) . Rat neuroblastoma B103 cells, maintained in complete media were transfected with each plasmid using GeneJET Plus (Thermo Scientific) (Fukushima et al., 1998) . After 24 hr incubation, media was replaced with complete media containing 1 mg/ml G418 (Life Technologies) and the cells were cultured for an additional 2 weeks. Cells labeled with anti-HA antibody (Roche) followed by PE-conjugated anti rat IgG (eBioscience) as primary and secondary antibodies, respectively, were sorted by FACS Aria II (BD Biosciences) using a PE-highly-positive gate, collected, and cultured in complete media containing Penicillin-Streptomycin (Life Technologies) to create stable lines.
For Ca 2+ measurement, the stable cell lines were starved with FreeStyle 293
Expression Medium (Life Technologies) for at least 1 hr before loading dye according to the manufacture's instruction with minor modifications (FLIPR Calcium 4 Assay Kit; Molecular Device). Intracellular Ca 2+ mobilization was monitored in response to increasing ligand concentration using a scanning fluorimeter (FLEXstation 3; Molecular Devices) at an excitation wavelength of 485 nm and an emission wavelength of 525 nm. For cAMP assay, stable cell lines were starved with FreeStyle 293 Expression Medium (Life Technologies) overnight. The cells were incubated with ligands for 30 min at room temperature in Hank's Balanced Salt Solution containing 10 mM forskolin and 0.5 mM 3-isobutyl-1-methylxanthine. Intracellular cAMP levels were determined using a cAMP-Screen System (Applied Biosystems) according to the manufacturer's instructions.
For neurite retraction and stress fiber formation assay, stable cell lines were starved with FreeStyle 293 Expression Medium (Life Technologies) overnight. The cells were incubated with ligands for 15 min at 37 C, washed and then fixed with 2% paraformaldehyde. Cells with round morphology lacking neurite extensions were counted and represented as a percentage of the observed cells. The f-actin stress fiber formation was studied using rhodamine phalloidin staining. Fixed cells were washed with 0.3% Triton X-100 in PBS, and stained with 1 mg/ml rhodamine-phalloidin for 30 min at room temperature. After washing, the cells were mounted using Vectorshield (Vector Laboratory). Images were captured using a Nikon C2 laser-scanning confocal microscope. Standard lipids were obtained from commercial sources: 1-oleoyl-LPA and 1-arachidonoyl-LPA (Avanti Polar Lipids), AEA, 2-AG and pAEA (Cayman Chemical). Enzymatic synthesis was employed for 2-arachidonoyl-LPA that was enzymatically synthesized from 1,2-diarachidonoyl-sn-glycero-3-phosphate (diarachidonoyl-PA) (Avanti Polar lipids) using Rhizopus arrhizus lipase (Sigma) (see also Supplemental Experimental Procedures).
ACCESSION NUMBERS
Coordinates and structures factors have been deposited in the Protein Data Bank for LPA1-ONO9780307, LPA1-ONO9910539 and LPA1-ONO3080573 (PDB: 4Z34, 4Z35, 4Z36). 
